celecoxib

ApprovedCompleted

0 watching 0 views this week🔥 Hot

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Knee Osteoarthritis

Conditions

Knee Osteoarthritis

Trial Timeline

Jun 1, 2004 → Sep 1, 2005

NCT ID

NCT00194090

About celecoxib

celecoxib is a approved stage product being developed by Pfizer for Knee Osteoarthritis. The current trial status is completed. This product is registered under clinical trial identifier NCT00194090. Target conditions include Knee Osteoarthritis.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (15)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00976716	Phase 3	Completed	Sep 1, 2009	Nov 1, 2009	Pain
NCT00585156	Phase 1	Terminated	Jun 1, 2008	Sep 1, 2008	Bone Ingrowth
NCT00474773	Pre-clinical	Completed	Jun 1, 2007	Dec 1, 2009	Pain Management
NCT00304317	Approved	Withdrawn	Mar 1, 2006	Aug 1, 2008	Ureteral Calculi
NCT00296127	Phase 1	Completed	Feb 1, 2006	Mar 1, 2006	Healthy Volunteers
NCT00151476	Pre-clinical	Terminated	Nov 1, 2004	Nov 1, 2008	Familial Adenomatous Polyposis (FAP)
NCT00163241	Phase 3	Terminated	Jun 1, 2004	Jan 1, 2006	Osteoarthritis
NCT00194090	Approved	Completed	Jun 1, 2004	Sep 1, 2005	Knee Osteoarthritis
NCT00633438	Approved	Completed	Jan 1, 2004	Jun 1, 2004	Arthroscopy
NCT00638807	Approved	Completed	Dec 1, 2003	Jul 1, 2004	Osteoarthritis, Knee
NCT00181532	Phase 2	Completed	May 1, 2003	Jan 1, 2008	Non Small Cell Lung Carcinoma
NCT00633386	Approved	Completed	Feb 1, 2003	Aug 1, 2003	Arthroscopy
NCT00136487	Phase 2/3	Completed	Oct 1, 2002	Sep 1, 2006	Prostate Cancer
NCT00141193	Phase 3	Completed	Feb 1, 2001	May 1, 2007	Colorectal Adenoma
NCT00036283	Phase 2	Completed	Nov 1, 2000	Apr 1, 2004	Precancerous Conditions

Competing Products

20 competing products in Knee Osteoarthritis

See all competitors

Product	Company	Stage	Hype Score
LY2828360 + Placebo	Eli Lilly	Phase 2	52
UBX0101 or placebo	Unity Biotechnology	Pre-clinical	15
UBX0101	Unity Biotechnology	Phase 1	25
UBX0101	Unity Biotechnology	Phase 2	44
UBX0101	Unity Biotechnology	Phase 1	25
YH23537 + Celecoxib + YH23537 placebo	Yuhan	Phase 2	52
YM150 + Warfarin	Astellas Pharma	Phase 2	52
ASP7962 + Naproxen + Placebo	Astellas Pharma	Phase 2	52
Capsaicin Topical Solution	Astellas Pharma	Approved	85
CGS-200-1 + CGS-200-5 + CGS-200 Vehicle	Astellas Pharma	Phase 2	52
MM-II dose I + MM-II dose II + MM-II dose III + Placebo + Placebo + Placebo	Sun Pharmaceutical	Phase 2	52
Duloxetine + Placebo	Shionogi	Phase 3	77
Duloxetine	Shionogi	Phase 3	77
V120083 + Naproxen + Placebo	Shionogi	Phase 2	52
ONO-4474 + Placebo matching ONO-4474	Ono Pharmaceutical	Phase 2	52
Duloxetine + Placebo	Eli Lilly	Phase 3	77
Duloxetine (DLX) + Placebo (PLA)	Eli Lilly	Phase 3	77
Duloxetine + placebo	Eli Lilly	Phase 3	77
Placebo + LY545694 49 mg + LY545694 105 mg	Eli Lilly	Phase 2	52
LY517717 + enoxaparin	Eli Lilly	Phase 2	52

Other Products from Pfizer